Ketamine Tablets vs Intramuscular Injection

Ketamine Tablets vs Intramuscular Injection

Intramuscular (IM) ketamine injection and oral ketamine tablets represent two different treatment philosophies: IM delivers a potent, clinic-based experience with high bioavailability, while tablets prioritize accessibility and gentleness for ongoing home-based care. Each has a distinct clinical role.

How They Work

Ketamine tablets: Swallowed and absorbed through the GI tract. Extensive first-pass hepatic metabolism reduces bioavailability to 10-25%. Produces a gradual, extended experience with significant norketamine generation due to the oral bioavailability profile.

IM ketamine: Injected into a large muscle (typically deltoid or gluteal). Absorbed directly into systemic circulation through muscle capillaries, bypassing the liver entirely on first pass. Bioavailability of 90-95% — nearly matching IV.

Side-by-Side Comparison

Bioavailability and Potency

The bioavailability gap is enormous. An IM dose is roughly 4-8 times more efficient per milligram than an oral dose. See our dosing guide for how oral doses are calibrated to account for this difference.

Onset and Duration

Tablets: Onset in 30-60 minutes, peak at 1-2 hours, total duration 3-5 hours.

IM: Onset in 3-5 minutes, peak at 15-30 minutes, total duration 1-2 hours. The rapid onset and relatively short duration make IM pharmacokinetically similar to IV but without requiring venous access.

Setting

Tablets: Home-based with a treatment monitor. No needles, no clinic visit required.

IM: Requires a clinical setting with a trained provider to administer the injection. Monitoring during the session is standard. Some ketamine-assisted psychotherapy practices prefer IM because it avoids the complexity of IV access while delivering a potent experience.

Patient Experience

Tablets: Gradual, mild to moderate effects. Most patients remain conversational. The experience is often described as a "softening" rather than a dramatic altered state.

IM: Rapid, intense onset. At standard doses, significant dissociation occurs within minutes. The experience is closer to IV than to oral — immersive, potentially profound, and resolving relatively quickly.

Pain of Administration

Tablets: None — simply swallowed.

IM: A brief injection. Ketamine can cause a mild burning sensation at the injection site. The discomfort is minor and brief for most patients, but needle-averse individuals may find it distressing.

Cost

Tablets: $8-$30 per dose from compounding pharmacies, plus clinical oversight costs.

IM: $200-$600 per session at most clinics, including the injection and monitoring. Less expensive than IV infusion but substantially more than tablets.

When Tablets Are the Better Choice

• Maintenance therapy over months or years
• Home-based treatment when clinic visits are impractical
• Patients who prefer a milder, more gradual experience
• Cost-sensitive situations
• Needle-averse patients
• Daily or near-daily dosing protocols for pain

When IM Is the Better Choice

• Acute treatment requiring potent per-session effects
• Ketamine-assisted psychotherapy (where the dissociative experience is therapeutically leveraged)
• Patients who need high bioavailability without IV access
• Settings where oral absorption is unreliable (GI conditions, nausea)
• Clinics that do not have IV infusion capability but can administer injections

Clinical Considerations

IM ketamine occupies a middle ground that makes it uniquely useful in certain clinical contexts. It delivers nearly IV-level bioavailability with simpler logistics — no IV line, no infusion pump, no extended infusion time. A single injection can be administered in minutes, with monitoring for 1-2 hours afterward.

For ketamine-assisted psychotherapy, many practitioners prefer IM because it produces a rapid, predictable altered state that lasts long enough for a meaningful therapy session (60-90 minutes) without the extended duration of oral dosing.

Tablets, by contrast, are the workhorse of maintenance therapy. Their lower potency per session is offset by the ability to dose frequently at home, making them the practical choice for long-term treatment.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions

Quick Answer

Oral ketamine tablets and intramuscular (IM) ketamine injections sit on opposite ends of the bioavailability and onset spectrum. Swallowed tablets deliver roughly 17-24% bioavailability with a 30-60 minute onset; IM injection delivers 90-93% bioavailability with a 3-5 minute onset. Tablets are designed for at-home, lower-intensity protocols; IM is a clinic-only route requiring monitoring. Neither route is appropriate for patients with uncontrolled hypertension, active psychosis, or pregnancy without specialist supervision.

Frequently Asked Questions

What is the difference between IV and IM ketamine?

Intravenous (IV) ketamine is infused directly into a vein, giving 100% bioavailability and full prescriber control over dose curve. Intramuscular (IM) is injected into the deltoid or gluteal muscle, giving 90-93% bioavailability with a 3-5 minute onset. IV allows immediate dose adjustment mid-session; IM is single-shot and easier to administer but less titratable.

Is ketamine IM bioavailability really 90%?

Yes — published pharmacokinetic studies place IM ketamine bioavailability at 90-93%. The remaining 7-10% loss reflects local tissue binding and minor pre-systemic metabolism at the injection site. By contrast, swallowed oral tablets land at 17-24% because of extensive first-pass hepatic metabolism.

How does subcutaneous ketamine compare to intramuscular?

Subcutaneous (SC) ketamine reaches roughly 80-90% bioavailability, slightly below IM's 90-93%, with a marginally slower 5-10 minute onset. SC is favored in palliative-care and home-infusion contexts where vascular access is impractical. Neither SC nor IM is comparable to a swallowed tablet, which sits in the 17-24% bioavailability range.

Why would a prescriber choose tablets over IM?

Tablets enable at-home, lower-intensity maintenance protocols without the need for a clinic visit, IV access, or in-room monitoring. They are appropriate for patients who have responded to a supervised induction and need a gentler ongoing regimen. IM remains preferred for rapid-onset, higher-intensity sessions where clinic monitoring is feasible.